Citations

Showing 10 of 108162 citations.

Associations of sleep and female sexual function: good sleep quality matters
Kling, Juliana M. , Kapoor, Ekta , Mara, Kristin C. , Mara, Kristin, Mara, Kristin C , Kling, Juliana M , Kapoor, Ekta , Faubion, Stephanie S.

Mayo Clinic

Menopause | April 21, 2021 | Volume: 28 | Issue: 6 | Pages: 619-625

10.1097/gme.0000000000001744 | PMID 33878089 Get It

Abstract Objective: To evaluate associations between sleep and female sexual function. Methods: A cross-sectional analysis from the Data Registry on Experiences of Aging, Menopause and Sexuality (DREAMS) was performed using questionnaires in women presenting for menopause or sexual health consult at Mayo Clinic from December, 2016 to September, 2019. Female Sexual Function Index (FSFI), Female Sexual Distress Scale-Revised (FSDS-R), and the Pittsburgh Sleep Quality Index (PSQI) assessed sexual function and sleep parameters, respectively. Associations between sleep quality (PSQI score ≥ 5 poor sleep quality), sleep durations (< 5 h, 5-6 h, 6-7 h, > 7 h) and female sexual dysfunction (FSFI ≤ 26.55 and FSDS-R ≥ 11) were evaluated utilizing a multivariable logistic model adjusting for multiple factors. A secondary analysis evaluated sleep quality by sexual activity and also included sexually inactive women. Results: A total of 3,433 women were included (mean age 53). Sexually active women (N = 2,487; 72.4%) were included in the primary analysis; 75% had poor sleep quality, and 54% met criteria for female sexual dysfunction. On multivariable analysis, women with poor sleep quality were 1.48 times more likely to report female sexual dysfunction (95% CI 1.21-1.80, P < 0.001). Of women who reported sleeping < 5 hours nightly, 63.3% had female sexual dysfunction, and their Female Sexual Function Index total and domain scores were significantly lower than women sleeping > 7 hours nightly (P = 0.004); however, this was not statistically significant in multivariable analysis. Sexually active women were more likely to report good sleep quality compared with sexually inactive women (25.3% vs 20.5%, P = 0.003). Conclusions: Poor sleep quality, but not sleep duration, was associated with greater odds of female sexual dysfunction. Good sleep quality was linked to sexual activity. In addition to its myriad effects on health, poor sleep quality is associated with female sexual dysfunction. Video Summary: http://links.lww.com/MENO/A714.
Clinical Neurophysiology Fellowship Program Directors Survey on a Standardized Fellowship Match Process: A Call for Action
Liu, Lynn , Bensalem‐Owen, Meriem, LaRoche, Suzette M. , Nuwer, Marc R. , Lee, Leslie H., Rubin, Devon I., Laughlin, Ruple S. , Karakis, Ioannis , López, Jaime R. , Schmitt, Sarah E , Britton, Jeffrey W. , Sinha, Saurabh R.

Mayo Clinic

Journal of Clinical Neurophysiology | April 21, 2021 | Volume: 39 | Issue: 7 | Pages: 561-566

10.1097/wnp.0000000000000852 | PMID 33878059 Get It

Purpose: To survey US Clinical Neurophysiology (CNP) fellowship program directors on the nature of CNP and related training programs, current recruitment cycle, and views for a standardized process. Methods: A 23-question electronic survey was sent to all 93 US Accreditation Council for Graduate Medical Education-accredited CNP fellowship program directors from December 2020 to January 2021. Results: The response rate was 60%. There was great variability in the number of CNP positions and CNP tracks offered. The following tracks were identified: 48% EEG dominant, 26% EMG dominant, 22% split equally between EEG and EMG, and 2% and 1% were neurophysiologic intraoperative monitoring and autonomic dominant, respectively. Of the responding institutions, 43% offered a second year of training options to CNP fellows, mainly in conjunction with Epilepsy fellowship, which was pursued by 25% of CNP fellows. Many programs indicated flexibility in their design between different CNP tracks or between CNP and other related training programs based on the available candidates. The median percentage of CNP fellowship positions filled over the last 5 years was 80%, and there was great variation in the recruitment timeline across institutions. Overall, 86% of program directors favored a universal timeline and 71% favored a formal match for CNP. The respondents were split between an independent CNP match (39%) and joining the initiatives of affiliate societies on a standardized process (61%). Conclusions: There is significant heterogeneity in the makeup of the CNP fellowship programs and the recruitment process. The majority of CNP program directors are in favor of standardization of the recruitment process.
IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis
Sidana, Surbhi , Dasari, Surendra , Kourelis, Taxiarchis , Murray, David , King, Rebecca L. , McPhail, Ellen D. , Kumar, Shaji , Gertz, Morie A. , Murray, David L., McPhail, Ellen Darcy , Gertz, Morie A , Sidana, Surbhi , Dispenzieri, Angela , Ramı́rez-Alvarado, Marina

Mayo Clinic

Blood Advances | April 21, 2021 | Volume: 5 | Issue: 8 | Pages: 2101-2105

10.1182/bloodadvances.2020003671 | PMID 33877297 Get It

Abstract Patients with immunoglobulin M (IgM) light chain (AL) amyloidosis have a distinct clinical presentation compared with those with non-IgM amyloidosis. We hypothesized that differential immunoglobulin light-chain variable region (IGVL) gene usage may explain the differences in organ involvement, because IGVL usage correlates with organ tropism. IGVL usage was evaluated by mass spectrometry of amyloid deposits (IgM, n = 45; non-IgM, n = 391) and differed across the 2 groups. In the λ family, LV2-08 (13% vs 2%; P &lt; .001) and LV2-14 (36% vs 10%; P &lt; .001) usage was more common in IgM vs non-IgM amyloidosis, whereas LV1-44 (0% vs 10%; P = .02) and LV6-57 (2% vs 18%; P = .004) usage was less common. In the κ family, there was a trend toward higher KV4-01 (11% vs 4%; P = .06) usage in IgM amyloidosis. IGVL usage correlated with disease characteristics/organ tropism. LV2-14 (more common in IgM amyloidosis) has historically been associated with peripheral nerve involvement and lower light chain burden, which were more frequent in IgM amyloidosis. LV1-44 (less common in IgM), associated with cardiac involvement, was less frequent in IgM patients. LV6-57 (less common in IgM) is associated with t(11;14), which was less frequent in IgM patients. In conclusion, IGVL gene usage differs in patients with IgM vs non-IgM amyloidosis and may explain the distinct clinical presentation.
Procyanidin C1 is a natural agent with senolytic activity against aging and age-related diseases
Xu, Qixia, Li, Zi , Liu, Hanxin , Wang, Ying , He, Ruikun , Zhang, Xuguang , Campisi, Judith , Kirkland, James L. , Fu, Qiang , Li, Zi, Lin, Xu , Sun, Yu

Mayo Clinic

No container title available | April 21, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-421222/v1 Get It

Abstract Aging causes functional decline of multiple organs and increases the risk of age-related pathologies. In advanced lives, accumulation of senescent cells, which develop the senescence-associated secretory phenotype (SASP), promotes chronic inflammation and causes diverse conditions. Here we report the frontline outcome of screening a natural product library with human primary stromal cells as an experimental model. Multiple candidate compounds were assayed, and grape seed extract (GSE) was selected for further investigation due to its leading capacity in targeting senescent cells. We found procyanidin C1 (PCC1), a polyphenolic component, plays a critical role in mediating the antiaging effects of GSE. PCC1 blocks the SASP expression when used at low concentrations. Importantly, it selectively kills senescent cells upon application at higher concentrations, mainly by enhancing production of reactive oxygen species (ROS) and disturbing mitochondrial membrane potential, processes accompanied by upregulation of Bcl-2 family pro-apoptotic factors Puma and Noxa in senescent cells. PCC1 depletes senescent cells in treatment-damaged tumor microenvironment (TME) and enhances therapeutic efficacy when combined with chemotherapy in preclinical assays. Intermittent administration of PCC1 to both senescent cell-implanted mice and naturally aged animals alleviated physical dysfunction and prolonged post-treatment survival, thus providing substantial benefits in late life stage. Together, our study identifies PCC1 as a distinct natural senolytic agent, which may be exploited to delay aging and control age-related pathologies in future medicine.
Acute appendicitis complicated by concomitant thyroid storm
Mohseni, Michael , Graham, Charles, Mohseni, Michael M., Mohseni, Michael M , Graham, Charles

Mayo Clinic

Baylor University Medical Center Proceedings | April 21, 2021 | Volume: 34 | Issue: 4 | Pages: 484-485

10.1080/08998280.2021.1906829 | PMID 34219931 Get It

High-Fidelity Control of Spin Ensemble Dynamics via Artificial Intelligence: From Quantum Computing to Imaging
Manu, V. S., Pavuluri, KowsalyaDevi , Mullen, Michael , Garwood, Michael , Veglia, Gianluigi

Mayo Clinic

No container title available | April 20, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-403351/v1 Get It

Abstract High-fidelity control of spin ensemble dynamics is essential to many fields, spanning from quantum computing to optical, coherent, and nuclear magnetic resonance (NMR) spectroscopy and imaging (MRI). However, attaining robust and high-fidelity quantum spin operations remains an unmet challenge. Using a combination of an evolutionary algorithm and artificial intelligence, we designed time-optimal, radio frequency (RF) pulses with tunable spatial or temporal field inhomogeneity compensation and fidelity for unitary operations up to 0.9999. As a benchmark, we constructed a spin entanglement operator and a programmable quantum state creator for a weakly-coupled two-spin-1/2 system. We achieved high-fidelity transformations under multiple inhomogeneity sources. The newly designed RF pulses are more robust and less prone to imperfection than the commonly used shapes for basic liquid-state NMR experiments and reduce RF artifacts in MRI. This new strategy will enable the design of efficient quantum computing opera-tors as well as new spectroscopic and imaging techniques.
How Did a Multi-Institutional Trial Show Feasibility of Electronic Data Capture in Older Patients With Cancer? Results From a Multi-Institutional Qualitative Study (Alliance A171902)
Martin, Nichole , Harlos, Elizabeth, Cook, Kathryn , O’Connor, Jennifer M. , Dodge, Andrew , Guerard, Emily J., Lafky, Jacqueline M., Jatoi, Aminah , Le‐Rademacher, Jennifer , Martin, Nichole A, Harlos, Elizabeth S., Cook, Kathryn D, Le-Rademacher, Jennifer G , Dodge, Andrew B

Mayo Clinic

JCO Clinical Cancer Informatics | April 20, 2021 | Volume: No volume available | Issue: 5 | Pages: 442-449

10.1200/cci.20.00164 | PMID 33877885 Get It

PURPOSE New technology might pose problems for older patients with cancer. This study sought to understand how a trial in older patients with cancer (Alliance A171603) was successful in capturing electronic patient-reported data. METHODS Study personnel were invited via e-mail to participate in semistructured phone interviews, which were audio-recorded and qualitatively analyzed. RESULTS Twenty-four study personnel from the 10 sites were interviewed; three themes emerged. The first was that successful patient-reported electronic data capture shifted work toward patients and toward study personnel at the beginning of the study. One interviewee explained, “I mean it kind of lost all advantages…by being extremely laborious.” Study personnel described how they ensured electronic devices were charged, wireless internet access was up and running, and login codes were available. The second theme was related to the first and dealt with data filtering. Study personnel described high involvement in data gathering; for example, one interviewee described, “I answered on the iPad, whatever they said. They didn't even want to use it at all.” A third theme dealt with advantages of electronic data entry, such as prompt data availability at study completion. Surprisingly, some remarks described how electronic devices brought people together, “Some of the patients, you know, it just gave them a chance to kinda talk about, you know, what was going on.” CONCLUSION High rates of capture of patient-reported electronic data were viewed favorably but occurred in exchange for increased effort from patients and study personnel and in exchange for data that were not always patient-reported in the strictest sense.
Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib
Rhainds, David , Packard, Chris J. , Brodeur, Mathieu R., Niesor, Eric J. , Sacks, Frank M. , Jukema, J. Wouter , Wright, R. Scott , Waters, David D. , Heinonen, Therèse, Black, Donald M. , Laghrissi‐Thode, Fouzia , Dubé, Marie‐Pierre , Dubé, Marie-Pierre , Wright, R Scott , Pfeffer, Marc Alan , Tardif, Jean‐Claude

Mayo Clinic

Circulation: Genomic and Precision Medicine | April 20, 2021 | Volume: 14 | Issue: 2 | Pages: No page available

10.1161/circgen.121.003219 | PMID 33794646 Get It

Following the neutral results of the dal-OUTCOMES trial, a genome-wide study identified the rs1967309 variant in the adenylate cyclase type 9 ( ADCY9 ) gene on chromosome 16 as being associated with the risk of future cardiovascular events only in subjects taking dalcetrapib, a CETP (cholesterol ester transfer protein) modulator. Homozygotes for the minor A allele (AA) were protected from recurrent cardiovascular events when treated with dalcetrapib, while homozygotes for the major G allele (GG) had increased risk. Here, we present the current state of knowledge regarding the impact of rs1967309 in ADCY9 on clinical observations and biomarkers in dalcetrapib trials and the effects of mouse ADCY9 gene inactivation on cardiovascular physiology. Finally, we present our current model of the interaction between dalcetrapib and ADCY9 gene variants in the arterial wall macrophage, based on the intracellular role of CETP in the transfer of complex lipids from endoplasmic reticulum membranes to lipid droplets. Briefly, the concept is that dalcetrapib would inhibit CETP-mediated transfer of cholesteryl esters, resulting in a progressive inhibition of cholesteryl ester synthesis and free cholesterol accumulation in the endoplasmic reticulum. Reduced ADCY9 activity, by paradoxically leading to higher cyclic AMP levels and in turn increased cellular cholesterol efflux, could impart cardiovascular protection in rs1967309 AA patients. The ongoing dal-GenE trial recruited 6145 patients with the protective AA genotype and will provide a definitive answer to whether dalcetrapib will be protective in this population.
Prophylactic Drainage after Appendectomy for Perforated Appendicitis in Adults: A Post Hoc Analysis of an EAST Multi-Center Study
Qian, Sinong , Vasileiou, Georgia , Pust, Gerd Daniel , Zakrison, Tanya L. , Rattan, Rishi , Zielinski, Martin D. , Ray-Zack, Mohamed D. , Group, on behalf of the EAST Appendicitis Study, Alouidor, Reginald, Hing, Kailyn Kwong, Sharp, Victoria , Serena, Thomas , Kasotakis, George , Perez, Sean, Allmond, Stacie L., Long, Bruce, Barth, Nadine, Roman, Janika San, Lawless, Ryan A. , Cralley, Alexis , Gelbard, Rondi B. , Szczepanski, Crystal, Eyer, Steven D., Proulx, Kaitlyn, Wild, Jeffrey, Young, Katelyn , Teicher, Erik J. , Lita, Elena, Morris, David S. , Juarez, Laura, Catalano, Richard D., Turay, David, Roberts, Jennifer C., Kaafarani, Haytham M.A., Eid, Ahmed , Kanaan, Tala , Portillo, Victor, Collom, Morgan, Eddine, Savo Bou Zein , Tabrizi, Maryam B. , Elsharkawy, Ahmed Elsayed Mohammed , Yeh, D. Dante, Evans, David , Vázquez, Daniel , Saxe, Jonathan M. , Jacobson, Lewis E. , Behrens, Brandon, Joseph, Bellal , Mull, Jennifer, Pasley, Jason, O’Meara, Lindsay , Gök, Ali , To, Jocelyn, Bradley, Matthew J. , Zielinski, Martin, Zeeshan, Muhammad , Namias, Nicholas , Yeh, D. Dante , Group, on behalf of the EAST Appendicitis Study, Morris, David, Cullinane, Daniel C. , Roberts, Jennifer C., Dodgion, Christopher M. , Yeh, D. Dante, Vazquez, Daniel E., Schreiber, Martin J. , Nahmias, Jeffry T. , Sun, Beatrice J. , Crandall, Marie , Rodríguez, Carlos

Mayo Clinic

Surgical Infections | April 20, 2021 | Volume: 22 | Issue: 8 | Pages: 780-786

10.1089/sur.2019.258 | PMID 33877912 Get It